Unlock the Webinar Replay
Boost IL-4 Detection
50x with BOLD!
What You’ll Learn in This Webinar Recording
- The critical role of cytokines in immunology research
- How BOLD technology supercharges standard immunoassays
- Case study: Achieving a 50x lower limit of detection for IL-4
- Step-by-step guide to integrating BOLD into your assays
- Future applications for drug discovery and diagnostics
Peter walks you through optimizing a human IL-4 ELISA, achieving a limit of detection (LOD) of 0.040 pg/mL—nearly 50x better than the standard 1.9 pg/mL. This breakthrough not only accelerates biomarker discovery but also paves the way for less invasive testing and improved therapeutic monitoring.
Watch the Webinar Here
Enter your email to join Dr. Peter Stenlund as he reveals BOLD’s 50x sensitivity boost!
About Peter Stenlund
Dr. Peter Stenlund is an experienced protein chemist with a PhD in biochemistry from Umeå university. Briefly, from that point forward to his present position at Cavidi AB, he has been employed as a senior lecturer, as a post-doctoral scientist in USA, as a development scientist at Biacore and as a senior scientist at Octapharma and Galderma. His work has focused on analytical development aimed for characterization and release of protein drugs.
New Signal Amplification Method for Immunology Researchers
Detecting low-abundance biomarkers like cytokines is vital for advancing research in immunology, drug discovery, and disease monitoring. However, traditional assays often lack the sensitivity to detect trace amounts, especially in complex samples or small volumes. Enter BOLD (Binding Oligo Ladder Detection)—a game-changing technology from Cavidi. Watch the presentation on BOLD by our principal Scientist, Dr. Peter Stenlund
Enhancing IL-4 Detection with BOLD Technology
This webinar dives into how Exazym®’s BOLD technology transforms a standard human IL-4 sandwich ELISA. Dr. Peter Stenlund presents how BOLD achieves attomole-level detection of low-abundance biomarkers using existing workflows. Whether you’re studying allergic diseases, autoimmune disorders, or infectious pathogens, this recording offers actionable insights to boost your research.
Why BOLD Technology Matters
- Accessible: Easily integrate into existing immunoassay workflows
- Cost-effective: Achieve ultra-sensitive detection without expensive equipment
- Versatile: Applicable across various neurodegenerative diseases
BOLD Technology, developed by Cavidi, offers a groundbreaking approach to biomarker detection. This ultra-sensitive technology can be integrated into any immunoassay, enhancing the sensitivity by up to 100x and the limit of detection by up to 50x. BOLD Technology empowers researchers to achieve unprecedented accuracy in detecting even the most elusive biomarkers, driving forward the quest for early diagnosis and effective treatment.
The Real-World Impact of BOLD Technology
In this webinar, you’ll see how BOLD technology empowers researchers with:
- 50x improved sensitivity in cytokine detection
- Early disease insights from low-concentration samples
- Compatibility with small sample volumes and complex matrices
Cytokines like IL-4 are key to understanding immune responses in conditions such as asthma, allergies, and autoimmune diseases. Yet, their low concentrations—especially in blood or small animal samples—pose detection challenges. BOLD’s signal amplification tackles these hurdles, enhancing sensitivity up to 50x and enabling earlier, more precise analysis without invasive sampling.